Aim: To evaluate cyclin-dependent kinase inhibitor 2A (CDKN2A) and cytokeratin 7 (CK7) expression in cervical intraepithelial neoplasia (CIN) formalin-fixed samples. Materials and Methods: Staining with antibody clones G175-405 for CDKN2A and OV-TL 12/30 for CK7 were evaluated and the detection of protein expressions were compared in 147 patients with CIN. Results: Clinical follow-up of patients with CIN1 and CIN2 showed that most patients had a favorable outcome. Single CDKN2A or CK7 expression and their combined expression had a greater sensitivity and negative predictive value in CIN1, corresponding to the non-development of the disease. The positive predictive value of CDKN2A was greater than that of CK7. Combined expression of CDKN2A and CK7 showed that the sensitivity, specificity, positive predictive values, and negative predictive values had their maximum index in the CIN1 group. Analysis of combined expression of CDKN2A and CK7 showed that 85.7% of patients presented unfavorable clinical outcomes, with positive expression for both markers identified in CIN2. Conclusion: Combined expression of CK7 and CDKN2A was associated with a better diagnosis of CIN, and negative expression in CIN1/2 groups had a greater negative predictive value for patient clinical outcome.Persistent cervical infection caused by high-risk human papillomavirus (HPV) is necessary for the development of precursor lesions and cervical cancer (1). Although carcinogenesis does not progress in the majority of infected women, cervical cancer is still the second leading cause of cancer-related deaths worldwide (2, 3). Cervical intraepithelial neoplasia (CIN), and squamous intraepithelial lesion (SIL) correspond to different stages of epithelial proliferation of undifferentiated basal cells. This progresses from CIN1 [lowgrade (L)SIL], which is very similar to normal fullydifferentiated squamous epithelium, to high-grade CIN (CIN2/3) or high-grade (H)SIL, containing mostly undifferentiated cells, and then to cervical carcinoma (4-6). CIN1 (LSIL) and CIN3 (HSIL) are more easily classified, justifying conservative management for the former and ablation for the latter (6). However, the intermediate point of distinction for CIN2, between CIN1 and CIN3, is not always clear-cut; there is a significant, well-known interobserver variability in this diagnosis. Thus, the Lower Anogenital Squamous Terminology (LAST) Project recommends the use of p16 immunohistochemistry as an adjunct to the morphological assessment of biopsies when the differential diagnosis includes high-grade lesions (7, 8).Cyclin-dependent kinase 2A (CDKN2A) protein, also known as p16 INK4A , is a CDK inhibitor that blocks CDK4-and CDK6mediated phosphorylation of RB transcriptional corepressor 1 (RB) to inhibit E2F-dependent transcription and cell-cycle progression (9). It is a tumor-suppressor located at chromosome 9p21 (10), and it has been shown to be a surrogate marker of high-risk (HR) HPV oncogenic activity (11). Immunostaining of CDKN2A has an important value in the diagnosti...